Compare · BIO vs RPID
BIO vs RPID
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Rapid Micro Biosystems Inc. (RPID): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and RPID operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $7.80B, about 84.9x RPID ($91.9M).
- Over the past year, BIO is up 29.0% and RPID is down 43.6% - BIO leads by 72.6 points.
- RPID has hit the wire 17 times in the past 4 weeks while BIO has been quiet.
- BIO has more recent analyst coverage (12 ratings vs 10 for RPID).
- Company
- Bio-Rad Laboratories Inc.
- Rapid Micro Biosystems Inc.
- Price
- $291.34-0.99%
- $1.99-0.25%
- Market cap
- $7.80B
- $91.9M
- 1M return
- +13.28%
- -22.61%
- 1Y return
- +29.01%
- -43.61%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- 2021
- News (4w)
- 0
- 17
- Recent ratings
- 12
- 10
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest BIO
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
Latest RPID
- Director Lowenstein Inese was granted 12,787 shares, increasing direct ownership by 22% to 70,687 units (SEC Form 4)
- Director Pei Melinda Litherland was granted 12,787 shares, increasing direct ownership by 15% to 100,687 units (SEC Form 4)
- Director Malloy Kirk was granted 12,787 shares, increasing direct ownership by 27% to 60,687 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Wirtjes Sean M was granted 12,787 shares, increasing direct ownership by 2% to 568,981 units (SEC Form 4)
- PRESIDENT AND CEO Spignesi Robert G. Jr. was granted 12,787 shares, increasing direct ownership by 1% to 1,190,571 units (SEC Form 4)
- SEC Form SD filed by Rapid Micro Biosystems Inc.
- Rapid Micro Biosystems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Malloy Kirk was granted 19,300 shares, increasing direct ownership by 67% to 47,900 units (SEC Form 4)
- Director Lowenstein Inese was granted 19,300 shares, increasing direct ownership by 50% to 57,900 units (SEC Form 4)
- Director Pei Melinda Litherland was granted 19,300 shares, increasing direct ownership by 28% to 87,900 units (SEC Form 4)